A multilevel, navigation-based intervention led to more timely initiation of postoperative radiation therapy vs. usual ...
A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing ...
Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...
Understanding how tumors change their metabolism to resist treatments is a growing focus in cancer research. As cancer cells adapt to therapies, their metabolism often shifts, which can help them ...
Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...
A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.
Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...
In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...
Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback